Galena public offering to fund PhIII of cancer vaccine NeuVax
This article was originally published in Scrip
Executive Summary
US oncology-focused Galena Biopharma has announced the opening of an underwritten public offering of 15,156,250 units at $1.60 per unit, or total gross proceeds of $24.25 million, to raise funds for its latest ventures.